Since September 2017, 17 patients from our institution accepted to pay for OncoDNA testing. In France OncoDNA’s analyses are not reimbursed yet and when we propose this innovative approach to patients they usually accept (even if their incomes are restricted).
My presentation will focus on the social and medical profiles of the patients, the moment the tests were done and how I decided to use the results of those analyses. I will show that such a testing should be done as early as possible (even in the adjuvant setting in young high-risk breast cancer patients) because of multi-resistance to drugs that was highlighted for all the patients tested, which explained relatively short relapse after the end of the adjuvant chemotherapy. In my opinion OncoDNA’s analyses should be done just after the first relapse.
The more so as new treatments like palbociclib for breast cancer are now available in France both for first and second line of treatment at a cost of 2800 Euros a month. Knowing also that this kind of therapies are given on an average of 24 months in first line and 11 months in second line, the cost-effectiveness of this solution seems obvious to better identify the potential good and poor responders to these very expansive treatments for the National Health Insurance.
After a thesis in Medicine and a specialization in oncology at the University of Lyon in France with Pr JP. GERARD and Th. PHILIP, Dr. Wagner started as Medical Specialist in 1992 at the Centre de Lutte Contre Le Cancer Paul Strauss in Strasbourg, France for 4 years.
He is also Master in Science (genetics and immunology). He became Algologist and held the position of Medical Director at Strasbourg Liberal Oncology during 14 years. Since 2012, Dr. Wagner is the Medical Director of the Institut Andrée Dutreix in Dunkerque. Indeed, he joined the Clinique de Flandre in Coudekerque and the Hospital Centre in Calais as Oncologist and Algologist.
In 2017, Dr. Wagner founded the SHISSO (the International Society for Homeopathy as Supportive Care in Oncology). SHISSO is a learned society whose purpose is to facilitate and develop the practice, teaching, research and promotion of homeopathic therapies as part of supportive care in oncology.